Company overview
Exagen Inc. is a CAP-accredited and CLIA-certified rheumatology specialty laboratory providing advanced autoimmune disease diagnostics through its AVISE testing platform. The company offers comprehensive biomarker testing for diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE), rheumatoid arthritis, and other connective tissue diseases, featuring proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology and over 30 clinically relevant biomarkers.
Exagen is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include autoimmune disease diagnostics, lupus testing, rheumatology laboratory, biomarker testing, avise testing platform.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://exagen.com/
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- autoimmune disease diagnostics, lupus testing, rheumatology laboratory, biomarker testing, avise testing platform
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What regulatory certifications and accreditations does Exagen hold?
- Exagen is College of American Pathologists (CAP) accredited and CLIA certified. The company has also received conditional approval from the New York State Department of Health for its advanced lupus and rheumatoid arthritis diagnostic tests.
- What are Exagen's key proprietary testing technologies?
- Exagen's flagship technology is Cell-Bound Complement Activation Products (CB-CAPs), introduced in 2012, which provides 22% higher sensitivity for SLE than standard complement measures. The company also offers specialized biomarkers including Anti-C1q for lupus nephritis assessment, Anti-Phosphatidylserine/Prothrombin (PS/PT) for lupus anticoagulant correlation, and Anti-CarP for rheumatoid arthritis erosive disease risk assessment.
- What clinical performance metrics does AVISE Lupus demonstrate?
- AVISE Lupus achieves 80% sensitivity and 86% specificity for SLE diagnosis and offers 48% greater sensitivity than traditional anti-dsDNA testing alone. The test incorporates 10 markers including anti-dsDNA, anti-Smith, and CB-CAPs levels in a tiered assessment algorithm.
Related editorial coverage
- Brazilian Oncology Market: Growth of Precision Medicine & Biomarker Testing
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
